Overview

Active Pass Pharmaceuticals is focused on the discovery and early clinical development of novel drugs that target molecular pumps transporting molecules that regulate ATP-binding cassette transporters, or ABC transporters. ABC transporter substrates and associated diseases include the b-amyloid peptide that aggregates in the brain to cause Alzheimer’s disease; all-trans retinal, whose inefficient removal from the retina causes macular degeneration; and cholesterol, which deposits in the vasculature to cause atherosclerosis.

Active Pass has established a program in Alzheimer’s disease therapeutics based on its proprietary suite of brain-expressed ABC transporters, and is pursuing new therapeutic opportunities by employing a chemogenomic strategy.

Partners

Collaboration for ABC transporter gene expression and drug discovery: Tranzyme Inc.